Cao Yanna, Jin Yan, Yu Jinpu, Wang Jingfu, Yan Jie, Zhao Qiang
Department of Pediatric Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, P.R. China.
Department of Cancer Molecular Diagnostic Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, P.R. China.
Oncotarget. 2017 Mar 14;8(11):18444-18455. doi: 10.18632/oncotarget.14408.
Neuroblastoma, the most common extracranial solid tumor among children, is an embryonal tumor originating from undifferentiated neural crest cell. Neuroblastomas are highly heterogeneous, represented by the wide range of clinical presentations and likelihood of cure, ranging from spontaneous regression to relentless progression despite rigorous multimodal treatments. Approximately, 50% of cases are high-risk with overall survival rates less than 40%. With the efforts to collect large numbers of clinically annotated specimens and the advancements in technologies, researchers have revealed numerous genetic alterations that may drive tumor growth. However, the most lack mutations in genes that are recurrently mutated, which inspires researchers to identify disrupted pathways instead of single mutated genes to unearth biological systems perturbed in neuroblastoma. Stratification of patients and target therapy based on their molecular signatures have been the center of focus. This review provides a comprehensive summary of the recent advances in identification of candidate genes variations, targeted approaches to high-risk neuroblastoma and evaluates the methods utilized for detection, which will provide new avenues to develop therapies and further genetic researches.
神经母细胞瘤是儿童最常见的颅外实体瘤,是一种起源于未分化神经嵴细胞的胚胎性肿瘤。神经母细胞瘤具有高度异质性,临床表现和治愈可能性差异很大,从自发消退到尽管进行了严格的多模式治疗仍无情进展。大约50%的病例为高危,总体生存率低于40%。随着收集大量临床注释标本的努力以及技术的进步,研究人员已经揭示了许多可能驱动肿瘤生长的基因改变。然而,最缺乏的是反复突变基因中的突变,这促使研究人员识别被破坏的通路而非单个突变基因,以挖掘神经母细胞瘤中受到干扰的生物系统。基于患者分子特征的分层和靶向治疗一直是关注的焦点。本综述全面总结了候选基因变异鉴定、高危神经母细胞瘤靶向治疗方法的最新进展,并评估了所使用的检测方法,这将为开发治疗方法和进一步的基因研究提供新途径。